Applying New Clinical Data to Practice: CCO Independent Conference of the 2021 Virtual ESMO Annual Meeting*

Download All
September 16-21, 2021; Virtual
Review experts’ conference preview commentary, Capsule Summary slidesets, and an expert analysis of key studies from the 2021 Virtual ESMO Congress.

Capsule Summary Slidesets

Among patients with muscle-invasive bladder cancer, dose-dense MVAC significantly improved the 3-year rate of PFS and time to progression vs gemcitabine plus cisplatin in the neoadjuvant setting.

Released: September 27, 2021

In a head-to-head trial in patients with previously treated HER2-positive metastatic breast cancer, trastuzumab deruxtecan reduced risk of disease progression or death by 72% compared with trastuzumab emtansine, a current standard of care.

Released: September 23, 2021

In this combined analysis from the ongoing STAMPEDE platform trial, 2 years of abiraterone acetate plus prednisolone added to ADT was associated with a significant improvement in metastasis-free survival and OS in patients with high-risk nonmetastatic prostate cancer.

Released: September 30, 2021

In this randomized, phase III trial, the addition of abiraterone to ADT plus docetaxel was associated with a significant improvement in rPFS and overall survival in men with de novo metastatic CSPC.

Released: September 27, 2021

With additional follow-up, nivolumab + CT continued to show an OS benefit over CT alone in previously untreated patients with advanced gastroesophageal cancers.

Released: September 28, 2021

[vic]-Trastuzumab duocarmazine, a novel antibody–drug conjugate, improved median PFS vs physician’s choice therapy in pretreated HER2+ locally advanced or metastatic breast cancer.

Released: September 28, 2021

Addition of pembrolizumab to chemotherapy improved both OS and PFS in patients with locally recurrent unresectable or metastatic triple-negative breast cancer with PD-L1 CPS ≥10.

Released: September 28, 2021

In patients with colorectal cancer and unresectable liver metastases, the addition of transarterial radioembolization with yttrium-90 to second-line chemotherapy demonstrated significant improvements in PFS and hepatic PFS with a higher rate of grade ≥3 toxicity.

Released: October 1, 2021

Phase Ib results suggest cabozantinib plus atezolizumab may be active in mCRPC patients with visceral or extrapelvic lymph node metastases.

Released: September 21, 2021

In this single-arm study in patients with previously treated HER2-mutated NSCLC, trastuzumab deruxtecan demonstrated robust antitumor activity with a safety profile consistent with previous reports.

Released: September 27, 2021

In this phase I study subset analysis, datopotamab deruxtecan demonstrated antitumor activity and manageable toxicity in patients with heavily pretreated advanced NSCLC with actionable genomic alterations.

Released: September 30, 2021

In this single-arm phase II trial, second-line therapy with trastuzumab deruxtecan showed a response rate of 38% and durable responses following a trastuzumab-containing regimen in Western patients with HER2+ advanced gastric or GEJ cancer with no unexpected adverse events.

Released: September 22, 2021

After a median follow-up of more than 3 years, this update showed sustained overall survival benefit with adding durvalumab to etoposide/platinum chemotherapy for the first-line treatment of patients with extensive-stage SCLC.

Released: September 23, 2021

In this final analysis of the landmark COSMIC-311 trial, cabozantinib maintained a significant PFS benefit vs placebo in patients with radioiodine-refractory/-ineligible differentiated thyroid cancer after prior VEGFR TKI therapy.

Released: September 29, 2021

In patients with previously treated mCRPC, the addition of 177Lu-PSMA-617 to standard of care resulted in improvements in health-related quality of life and time to worsening of pain and first symptomatic skeletal events, in addition to the previously reported OS and rPFS benefits.

Released: September 30, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Exelixis, Inc.
Ipsen Biopharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue